Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity
Advanced Science · 2024-01 · 11 (3)
DOI: 10.1002/advs.202306580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 20.11.2023. Verfasst von Yongjuan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou, He…. Hauptthemen laut MEDLINE: Nanomedicine, Apoptosis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhengzhou University, National University of Singapore.
Abstract (Originalsprache)
Cancer immunotherapy has become a mainstream cancer treatment over traditional therapeutic modes. Cancer cells can undergo programmed cell death including ferroptosis, pyroptosis, autophagy, necroptosis, apoptosis and cuproptosis which are find to have intrinsic relationships with host antitumor immune response. However, direct use of cell death inducers or regulators may bring about severe side effects that can also be rapidly excreted and degraded with low therapeutic efficacy. Nanomaterials are able to carry them for long circulation time, high tumor accumulation and controlled release to achieve satisfactory therapeutic effect. Nowadays, a large number of studies have focused on nanomedicines‐based strategies through modulating cell death modalities to potentiate antitumor immunity. Herein, immune cell types and their function are first summarized, and state‐of‐the‐art research progresses in nanomedicines mediated cell death pathways (e.g., ferroptosis, pyroptosis, autophagy, necroptosis, apoptosis and cuproptosis) with immune response provocation are highlighted. Subsequently, the conclusion and outlook of potential research focus are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- The center of Infection and Immunity, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, 1…
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.
- Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
ORCID-Profile: Weijing Yang
Förderung
- National Natural Science Foundation of China
- Zhengzhou University
- National University of Singapore
Zitieren
APA
Li, Y., Guo, Y., Zhang, K., Zhu, R., Chen, X., Zhang, Z., & Yang, W. (2024). Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity. Advanced Science, 11(3). https://doi.org/10.1002/advs.202306580
Vancouver
Li Y, Guo Y, Zhang K, Zhu R, Chen X, Zhang Z, et al. Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity. Advanced Science. 2024;11(3). doi:10.1002/advs.202306580
BibTeX
@article{Li2024,
author = {Li, Yongjuan and Guo, Yichen and Zhang, Kaixin and Zhu, Rongrong and Chen, Xiaoyuan and Zhang, Zhenzhong and Yang, Weijing},
title = {Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {3},
doi = {10.1002/advs.202306580}
}
EUVIMED